Close Menu

Amgen

The project is funded with £50 million from the UK government, £50 million from the Wellcome Trust, and £100 million from four pharmaceutical firms.

Consenting participants will have their deidentified sequence data used for research and will also have the chance to learn if they have clinically actionable results.

The partners are both "investing heavily" in the study and will have access to the data and to new technologies and interventions.

The companies will develop analytics tools and leverage the Syapse Learning Health Network in an effort to shorten the time to market for new cancer therapies.

In PNAS this week: core Pseudomonas aeruginosa genome, study of ancient Paget's disease of the bone, and more.

In Science this week: high-resolution map of human genetic recombination, and more.

Results from two GWAS studies suggest that 15-LO inhibitors could be a viable treatment for nasal polyps and chronic rhinosinusitis.

The firm is using collaborations to access the large, diverse cohorts it needs to support its goal of commercializing its SomaScan system as a clinical platform.

The companies will use Somalogic's SomaScan proteomic platform to measure levels of as many as 5,000 proteins in up to 40,000 of DeCode's patient samples.

A GWAS meta-analysis involving hundreds of thousands of cases and controls led to new and known gallstone disease-associated variants at 28 loci.

Pages

The Lancet and the New England Journal of Medicine have retracted two COVID-19 papers due to concerns about the data used in their analyses.

A new study finds that three dimensional facial scans may be able to aid in diagnosing rare genetic diseases.

Lawmakers plan to introduce a bill that aims to prevent the theft of US-funded research, according to the Wall Street Journal.

In Science this week: analysis of ancient Caribbean islanders' genomes suggests at least three waves of migration into the region,  DNA barcoding of microbial spores, and more.